Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data (2022)

First Author: Clarke C
Attributed to:  Evaluating new healthcare technologies in cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1371/journal.pone.0269192

PubMed Identifier: 35653395

Publication URI: http://europepmc.org/abstract/MED/35653395

Type: Journal Article/Review

Parent Publication: PLOS ONE

Issue: 6

ISSN: 1932-6203